1. Home
  2. RUM vs CGEM Comparison

RUM vs CGEM Comparison

Compare RUM & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rumble Inc.

RUM

Rumble Inc.

HOLD

Current Price

$9.50

Market Cap

1.8B

Sector

Technology

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$22.60

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RUM
CGEM
Founded
2013
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.4B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
RUM
CGEM
Price
$9.50
$22.60
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$30.13
AVG Volume (30 Days)
4.0M
673.3K
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
80.72
N/A
EPS
N/A
N/A
Revenue
$100,622,320.00
N/A
Revenue This Year
$209.98
N/A
Revenue Next Year
$40.99
$5.20
P/E Ratio
N/A
N/A
Revenue Growth
5.38
N/A
52 Week Low
$4.62
$5.68
52 Week High
$10.60
$23.19

Technical Indicators

Market Signals
Indicator
RUM
CGEM
Relative Strength Index (RSI) 70.60 69.69
Support Level $5.37 $16.40
Resistance Level $10.54 N/A
Average True Range (ATR) 0.75 1.19
MACD 0.24 0.25
Stochastic Oscillator 76.92 89.31

Price Performance

Historical Comparison
RUM
CGEM

About RUM Rumble Inc.

RUM Group Inc focused is to maximize the power of human imagination through an independent technology ecosystem built on privacy, resilience, and an open alternative to Big Tech. Rumble gives human creativity a voice, a video and media platform built for creators and audiences who value free expression. Quake AI is a cloud and AI-infrastructure business, delivering the compute, data-center capacity, and blockchain infrastructure for the agentic era.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: